Skip to content

aTyr Pharma ATYR Total debt

Total debt at other companies

Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$2.73M+27.7%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$3.3M+2.6%
Vor Biopharma logo
Vor BiopharmaVOR
$2.94M-90.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

Plus components not separately reported this period.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's total debt?
aTyr Pharma (ATYR) reported total debt of $12.3M in Q1 2026.
How has aTyr Pharma's total debt changed year-over-year?
aTyr Pharma's total debt decreased by 9.2% year-over-year, from $13.54M to $12.3M.
What is the long-term trend for aTyr Pharma's total debt?
Over 5 years (2020 to 2025), aTyr Pharma's total debt has grown at a 41.4% compound annual growth rate (CAGR), from $2.24M to $12.66M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.